| 摘要 |
FIELD: chemistry. ^ SUBSTANCE: invention relates to a novel crystalline form of a compound of formula (I), which has P2T antagonist properties and can be used to prevent arterial thrombotic complications in patients suffering from coronary artery disease, cerebrovascular and peripheral vascular diseases. The crystalline form of compound (I) is essentially a pure polymorph II, which is essentially in anhydrous form and which is characterised by X-ray powder diffraction pattern, having characteristic base peaks of high intensity at 5.5(0.1), 13.5(+0.1), 18.3(0.1), 22.7(0.1) and 24.3(0.1) 2, and has characteristic peaks at 5.5(0.1), 6.8(0.1), 10.6(0.1o), 13.5(0.1), 14.9(0.1), 18.3(0.1), 19.2(0.1), 22.7(+0.1), 24.3(0.1) and 27.1(0.1) 2. The differential scanning calorimetry curve of the said crystalline polymorph has melting onset point in the range of 136-139C. ^ EFFECT: invention also relates to a method of producing the disclosed polymorph, according to which a compound of formula (I) is crystallised from chloroform. ^ 9 cl, 6 dwg, 2 ex |
